ArticleCell reports2023
Single-cell RNA sequencing identifies a population of human liver-type ILC1s.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.Nature communications · 2026Trial
- L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.Nature communications · 2024Trial
- Group 2 innate lymphoid cells program pulmonary adaptive immunity via granulocyte-macrophage colony-stimulating factor.The Journal of allergy and clinical immunology · 2026Article
- Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation.Biology · 2026Review
- Long non-coding RNAs in glioblastoma: from molecular drivers to therapeutic targets.Frontiers in immunology · 2026Review
- Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.Hepatology (Baltimore, Md.) · 2025Review
- Multifaceted Role of ILCs in Metabolic Adaptations: From Adult to Neonate.European journal of immunology · 2025Review
- Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.Cancer discovery · 2025Article
- IL-17A-producing NKp44(-) group 3 innate lymphoid cells accumulate in Familial Adenomatous Polyposis duodenal tissue.Nature communications · 2025Article
- Role of liver-resident NK cells in liver immunity.Hepatology international · 2025Review
- A 41-marker 37-color full spectrum flow cytometry panel for the deep immunophenotyping of human peripheral and liver natural killer cells.Frontiers in immunology · 2025Article
- Dual signaling pathways of TGF-β superfamily cytokines in hepatocytes: balancing liver homeostasis and disease progression.Frontiers in pharmacology · 2025Review
- Immunological mechanisms underlying fibrotic diseases via single-cell technologies.Frontiers in immunology · 2025Review
- Tissue-specific features of innate lymphoid cells in antiviral defense.Cellular & molecular immunology · 2024Review
- The nuclear export protein XPO1 provides a peptide ligand for natural killer cells.Science advances · 2024Article
- Diversity of group 1 innate lymphoid cells in human tissues.Nature immunology · 2024Article
- No time to die: Epigenetic regulation of natural killer cell survival.Immunological reviews · 2024Review
- Defining the T cell transcriptional landscape in pediatric liver transplant rejection at single cell resolution.bioRxiv : the preprint server for biology · 2024Article
- Single nuclear RNA sequencing of terminal ileum in patients with cirrhosis demonstrates multi-faceted alterations in the intestinal barrier.Cell & bioscience · 2024Article
- Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.Cancer immunology research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 10 institutions in 2 countries.
Benjamin KrämerDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany. Electronic address: benjamin.kraemer@ukbonn.de.
Ansel P NalinMedical Scientist Training Program, The Ohio State University, Columbus, OH 43210, USA; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
Feiyang MaMolecular Cell and Developmental Biology, College of Life Sciences, University of California Los Angeles, Los Angeles, CA 90095, USA.
Sarah EickhoffInstitute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Philipp LutzDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Sonia LeonardelliInstitute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Felix GoeserDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Claudia FinnemannDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Gudrun HackDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Jan RaabeDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Michael ToVinhDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Sarah AhmadDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Christoph HoffmeisterDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Kim M KaiserDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Steffen ManekellerDepartment of Surgery, University of Bonn, 53127 Bonn, Germany.
Vittorio BranchiDepartment of Surgery, University of Bonn, 53127 Bonn, Germany.
Tobias BaldInstitute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Michael HölzelInstitute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Robert HüneburgDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany.
Hans Dieter NischalkeDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany.
Alexander SemaanDepartment of Surgery, University of Bonn, 53127 Bonn, Germany.
Bettina LanghansDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
Dominik J KaczmarekDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany.
Brooke BennerBiomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
Matthew R LordoMedical Scientist Training Program, The Ohio State University, Columbus, OH 43210, USA; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
Jesse KowalskiNationwide Children's Hospital, Columbus, OH, USA.
Adam GerhardtCollege of Medicine, University of Cincinnati, Cincinnati, OH 45221, USA.
Jörg TimmInstitute of Virology, University of Duesseldorf, 40225 Düsseldorf, Germany.
Marieta TomaDepartment of Pathology, University of Bonn, 53127 Bonn, Germany.
Raphael MohrDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany.
Andreas TürlerGeneral and Visceral Surgery, Johanniter Hospital, 53113 Bonn, Germany.
Arthur CharpentierDepartment of Otorhinolaryngology/Head and Neck Surgery, University of Bonn, 53127 Bonn, Germany; Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Tobias van BremenDepartment of Otorhinolaryngology/Head and Neck Surgery, University of Bonn, 53127 Bonn, Germany.
Georg FeldmannDepartment of Internal Medicine III, University of Bonn, 53127 Bonn, Germany.
Arne SattlerClinic for Surgery, Transplant Immunology Lab, Charité University Hospital Berlin, 10117 Berlin, Germany.
Katja KotschClinic for Surgery, Transplant Immunology Lab, Charité University Hospital Berlin, 10117 Berlin, Germany.
Ali T AbdallahInterdisciplinary Center for Clinical Research, RWTH Aachen University, 52074 Aachen, Germany.
Christian P StrassburgDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany.
Ulrich SpenglerDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
William E CarsonDivision of Surgical Oncology, Department of Surgery, Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, Columbus, OH 43210, USA.
Bethany L Mundy-BosseDivision of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Matteo PellegriniMolecular Cell and Developmental Biology, College of Life Sciences, University of California Los Angeles, Los Angeles, CA 90095, USA.
Timothy E O'SullivanDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 900953, USA.
Aharon G FreudDepartment of Pathology, Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA. Electronic address: aharon.freud@osumc.edu.
Jacob NattermannDepartment of Internal Medicine I, University of Bonn, 53127 Bonn, Germany; German Center for Infection Research (DZIF), 53127 Bonn, Germany.
University of Bonn · DEThe Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity of California, Los Angeles · USCharité - Universitätsmedizin Berlin · DEHeinrich Heine University Düsseldorf · DEJohanniter-Krankenhaus Bonn · DENationwide Children's Hospital · USRWTH Aachen University · DEUniversity of Cincinnati Medical Center · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MElucidation of Human Natural Killer Cell DevelopmentR01CA208353 · NCI · OHIO STATE UNIVERSITY · PI AHARON G FREUD · 2017 to 2026
$4.0MDysregulation of Innate Lymphoid Immunity in Acute Myeloid LeukemiaR01CA255860 · NCI · OHIO STATE UNIVERSITY · PI MUNDY-BOSSE, BETHANY, OAKES, CHRISTOPHER C. · 2021 to 2025
$2.5MTranscriptional mechanisms of natural killer cell responses during mouse cytomegalovirus infectionR01AI145997 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI O'SULLIVAN, TIMOTHY E · 2019 to 2023
$2.3MGroup 1 Innate Lymphoid Cell Dysregulation in Acute Myeloid LeukemiaF30CA250244 · NCI · OHIO STATE UNIVERSITY · PI LORDO, MATTHEW · 2022 to 2025
$193kThe role of Notch signaling in human natural killer cell functional maturationF30CA236063 · NCI · OHIO STATE UNIVERSITY · PI NALIN, ANSEL PETER · 2019 to 2020
$79kNCI NIH HHS F30 CA236063NCI NIH HHS F30 CA250244NCI NIH HHS L30 CA199447NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA208353NCI NIH HHS R01 CA255860NIAID NIH HHS R01 AI145997
Abstract
Group 1 innate lymphoid cells (ILCs) comprise a heterogeneous family of cytotoxic natural killer (NK) cells and ILC1s. We identify a population of "liver-type" ILC1s with transcriptional, phenotypic, and functional features distinct from those of conventional and liver-resident NK cells as well as from other previously described human ILC1 subsets. LT-ILC1s are CD49a
Indexed as
Immunity, InnateLymphocytesEndothelial CellsHumansKiller Cells, NaturalLiverSequence Analysis, RNATranscription FactorsTranscription Factorscirrhotic liverCP: Immunologycross-tissue ILC1human group 1 ILCILC1innate lymphoid cellliver environmentliver ILC1natural killer cellTGF-β
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.